## Gerald T Keusch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9662826/publications.pdf

Version: 2024-02-01

106 papers 5,556 citations

35 h-index 71 g-index

107 all docs

107
docs citations

107 times ranked

4756 citing authors

#	Article	IF	Citations
1	Infection and diabetes: The case for glucose control. American Journal of Medicine, 1982, 72, 439-450.	0.6	599
2	Quinolone Antibiotics Induce Shiga Toxin–Encoding Bacteriophages, Toxin Production, and Death in Mice. Journal of Infectious Diseases, 2000, 181, 664-670.	1.9	530
3	Vitamin E and Respiratory Tract Infections in Elderly Nursing Home Residents. JAMA - Journal of the American Medical Association, 2004, 292, 828.	3.8	263
4	Environmental Enteric Dysfunction: Pathogenesis, Diagnosis, and Clinical Consequences. Clinical Infectious Diseases, 2014, 59, S207-S212.	2.9	224
5	Hospital-Acquired Mucormycosis ( <i>Rhizopus rhizopodiformis</i> ) of Skin and Subcutaneous Tissue. New England Journal of Medicine, 1978, 299, 1115-1118.	13.9	223
6	The pathogenesis of Shigella Diarrhea. Journal of Clinical Investigation, 1972, 51, 1212-1218.	3.9	210
7	Health Innovation Networks to Help Developing Countries Address Neglected Diseases. Science, 2005, 309, 401-404.	6.0	168
8	A Prospective Study of Diarrhea and HIV-1 Infection among 429 Zairian Infants. New England Journal of Medicine, 1993, 329, 1696-1702.	13.9	151
9	Implications of Acquired Environmental Enteric Dysfunction for Growth and Stunting in Infants and Children Living in Low- and Middle-Income Countries. Food and Nutrition Bulletin, 2013, 34, 357-364.	0.5	146
10	In Vivo Transduction with Shiga Toxin 1-Encoding Phage. Infection and Immunity, 1998, 66, 4496-4498.	1.0	136
11	The Origin of COVID-19 and Why It Matters. American Journal of Tropical Medicine and Hygiene, 2020, 103, 955-959.	0.6	134
12	Stigma and global health: developing a research agenda. Lancet, The, 2006, 367, 525-527.	6.3	131
13	Zoonoses and marginalised infectious diseases of poverty: Where do we stand? Parasites and Vectors, 2011, 4, 106.	1.0	122
14	Mediation of Cryptosporidium parvum Infection In Vitro by Mucin-Like Glycoproteins Defined by a Neutralizing Monoclonal Antibody. Infection and Immunity, 2000, 68, 5167-5175.	1.0	117
15	Co-trimoxazole (Trimethoprim-sulfamethoxazole) An Updated Review of its Antibacterial Activity and Clinical Efficacy. Drugs, 1982, 24, 459-518.	4.9	94
16	Shiga Toxins 1 and 2 Translocate Differently across Polarized Intestinal Epithelial Cells. Infection and Immunity, 1999, 67, 6670-6677.	1.0	89
17	In vitro Encystation of Giardia lamblia: Large-Scale Production of In vitro Cysts and Strain and Clone Differences in Encystation Efficiency. Journal of Parasitology, 1991, 77, 974.	0.3	87
18	Pathogenesis of Bacterial Diarrheas. New England Journal of Medicine, 1971, 285, 831-841.	13.9	80

#	Article	IF	Citations
19	The Global Health System: Lessons for a Stronger Institutional Framework. PLoS Medicine, 2010, 7, e1000193.	3.9	77
20	Identification and characterization of taglin, a mannose 6-phosphate binding, trypsin-activated lectin from Giardia lamblia. Biochemistry, 1987, 26, 8669-8675.	1.2	74
21	Shigella toxin(s): Description and role in diarrhea and dysentery. , 1981, 15, 403-438.		72
22	New challenges in studying nutrition-disease interactions in the developing world. Journal of Clinical Investigation, 2008, 118, 1322-1329.	3.9	66
23	A comparison of HEp-2 cell invasion by enteropathogenic and enteroinvasiveEscherichia coli. FEMS Microbiology Letters, 1990, 69, 83-86.	0.7	65
24	The Global Health System: Actors, Norms, and Expectations in Transition. PLoS Medicine, 2010, 7, e1000183.	3.9	64
25	Group D Streptococcal Bacteremia, with Emphasis on the Incidence and Presentation of Infections Due toStreptococcus bovis. New England Journal of Medicine, 1973, 289, 1400-1403.	13.9	60
26	Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development. Lancet, The, 2021, 397, 1229-1236.	6.3	54
27	Comparison of Secretory and Histological Effects of Shigella and Cholera Enterotoxins in Rabbit Jejunum. Gastroenterology, 1975, 68, 309-317.	0.6	50
28	Infectious Disease Threats: A Rebound To Resilience. Health Affairs, 2021, 40, 204-211.	2.5	50
29	Attachment of <i>Cryptosporidium parvum</i> Infection and Immunity, 1998, 66, 3429-3432.	1.0	50
30	Shigellosis. Pediatric Infectious Disease Journal, 1989, 8, 713-719.	1.1	46
31	One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays. Microbial Pathogenesis, 1993, 14, 57-66.	1.3	45
32	Development of a <i>Bacillus subtilis</i> -Based Rotavirus Vaccine. Vaccine Journal, 2010, 17, 1647-1655.	3.2	44
33	Shigella Infections. Clinics in Gastroenterology, 1979, 8, 645-662.	0.6	43
34	Shiga Toxin: Purification, Structure, and Function. Clinical Infectious Diseases, 1991, 13, S293-S297.	2.9	41
35	Effect of Shigella Enterotoxin on Electrolyte Transport in Rabbit Ileum. Gastroenterology, 1975, 69, 1230-1237.	0.6	40
36	Combination Amphotericin B-Rifampin Therapy for Pulmonary Aspergillosis in a Leukemic Patient. Chest, 1976, 70, 681-683.	0.4	39

#	Article	IF	CITATIONS
37	PATHOGENESIS OF <i>SHIGELLA</i> DIARRHEA. III. EFFECTS OF SHIGELLA ENTEROTOXIN IN CELL CULTURE*,â€. Transactions of the New York Academy of Sciences, 1973, 35, 51-58.	0.2	38
38	Quantitation of the rabbit intestinal glycolipid receptor for Shiga toxin. Gastroenterology, 1989, 97, 384-391.	0.6	38
39	Pathogenesis of Bacterial Diarrheas. New England Journal of Medicine, 1971, 285, 891-900.	13.9	35
40	Micronutrients and Susceptibility to Infection. Annals of the New York Academy of Sciences, 1990, 587, 181-188.	1.8	35
41	Nutritional Effects on Response of Children in Developing Countries to Respiratory Tract Pathogens: Implications for Vaccine Development. Clinical Infectious Diseases, 1991, 13, S486-S491.	2.9	35
42	Nutritional Implications of Parasitic Infections. Nutrition Reviews, 2009, 39, 149-161.	2.6	35
43	Shiga Toxin: Intestinal Cell Receptors and Pathophysiology of Enterotoxic Effects. Clinical Infectious Diseases, 1991, 13, S304-S310.	2.9	34
44	Identification and Partial Purification of a Lectin on the Surface of the Sporozoite of Cryptosporidium parvum. Journal of Parasitology, 1992, 78, 886.	0.3	34
45	Antimicrobial Therapy for Enteric Infections and Typhoid Fever. Clinical Infectious Diseases, 1988, 10, \$199-\$205.	2.9	33
46	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXIII. Control of Infection to Reduce the Prevalence of Infantile and Childhood Malnutrition. Clinical Infectious Diseases, 1986, 8, 273-287.	2.9	31
47	Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine, 2011, 29, 4778-4784.	1.7	31
48	A Monkey Model for EnterohemorrhagicEscherichia coliInfection. Journal of Infectious Diseases, 2001, 184, 206-210.	1.9	30
49	Vitamin A Supplements â€" Too Good Not to Be True. New England Journal of Medicine, 1990, 323, 985-987.	13.9	29
50	[22] Shiga toxin: Production and purification. Methods in Enzymology, 1988, 165, 152-162.	0.4	28
51	A Vaccine against Rotavirus — When is Too Much Too Much?. New England Journal of Medicine, 1997, 337, 1228-1229.	13.9	28
52	Detection of Shiga-Like Toxin-Producing Escherichia coli in Ground Beef and Milk by Commercial Enzyme Immunoassay. Journal of Food Protection, 1996, 59, 344-349.	0.8	27
53	THE SUSCEPTIBILITY OF BACTEROIDES TO THE PENICILLINS AND CEPHALOTHIN. American Journal of the Medical Sciences, 1966, 251, 428-432,448.	0.4	26
54	The Global Health System: Linking Knowledge with Action—Learning from Malaria. PLoS Medicine, 2010, 7, e1000179.	3.9	26

#	Article	IF	Citations
55	Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine, 2010, 28, 6658-6665.	1.7	26
56	Prevalence of enteric viruses among hospital patients with AIDS in Kinshasa, Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 263-266.	0.7	25
57	14 C-Glucose Oxidation in Whole Blood: a Clinical Assay for Phagocyte Dysfunction. Infection and Immunity, 1972, 5, 414-415.	1.0	25
58	What do -omics mean for the science and policy of the nutritional sciences?. American Journal of Clinical Nutrition, 2006, 83, 520S-522S.	2.2	24
59	Induction of a phosphomannosyl binding lectin activity inGiardia. BioEssays, 1990, 12, 211-215.	1.2	22
60	Shigella Toxin and the Pathogenesis of Shigellosis. Novartis Foundation Symposium, 1985, 112, 193-214.	1.2	21
61	Primary amines and chloroquine inhibit cytotoxic responses to Shigella toxin and permit late antibody rescue of toxin treated cells. Biochemical and Biophysical Research Communications, 1984, 121, 69-76.	1.0	20
62	Host Defense Mechanisms in Protein Energy Malnutrition. , 1981, 135, 183-209.		20
63	Science, not speculation, is essential to determine how SARS-CoV-2 reached humans. Lancet, The, 2021, 398, 209-211.	6.3	18
64	Role of opsonins in clinical response to granulocyte transfusion in granulocytopenic patients. American Journal of Medicine, 1982, 73, 552-563.	0.6	17
65	Tapping the power of small institutions. Nature, 2003, 422, 561-562.	13.7	15
66	Stigma and global health: looking forward. Lancet, The, 2006, 367, 538-539.	6.3	15
67	Susceptibilities of Gram-Negative Bacteria to Combinations of Antimicrobial Agents In Vitro. Antimicrobial Agents and Chemotherapy, 1975, 8, 164-171.	1.4	14
68	Immature Circulating Lymphocytes In Severely Malnourished Guatemalan Children. Journal of Pediatric Gastroenterology and Nutrition, 1987, 6, 265-270.	0.9	14
69	Vitamin A deficiency: slow progress towards elimination. The Lancet Global Health, 2015, 3, e502-e503.	2.9	14
70	Clinical trials during epidemics. Lancet, The, 2017, 389, 2455-2457.	6.3	14
71	Effects of acute endotoxemia and glucose administration on circulating leukocyte populations in normal and diabetic subjects. Metabolism: Clinical and Experimental, 1978, 27, 889-899.	1.5	13
72	Impairment of hemolytic complement activation by both classical and alternative pathways in serum from patients with kwashiorkor. Journal of Pediatrics, 1984, 105, 434-436.	0.9	13

#	Article	IF	CITATIONS
73	Shigellosis., 1991,, 593-620.		13
74	RECEPTOR-MEDIATED ENDOCYTOSIS OF SHIGELLA CYTOTOXIN., 1981,, 95-112.		13
75	Ethics of randomized trials in a public health emergency. PLoS Neglected Tropical Diseases, 2018, 12, e0006313.	1.3	12
76	Biochemical Effects of Cholera Enterotoxin. II. Glucose Metabolism in the Intestine of the Infant Rabbit. Journal of Infectious Diseases, 1971, 124, 188-193.	1.9	10
77	[33] Shiga toxin as inhibitor of protein synthesis. Methods in Enzymology, 1988, 165, 231-235.	0.4	10
78	Antioxidants in Infection. Journal of Nutritional Science and Vitaminology, 1993, 39, S23-S33.	0.2	10
79	Shigellosis. , 1998, , 631-656.		9
80	Crystallization of the B chain of Shiga-like toxin I from Escherichia coli. Journal of Molecular Biology, 1991, 218, 691-694.	2.0	8
81	THE MULTILATERAL INITIATIVE ON MALARIA: PAST, PRESENT, AND FUTURE. American Journal of Tropical Medicine and Hygiene, 2004, 71, 279-282.	0.6	8
82	Kinetics of Absorption of Toxin of Vibrio cholerae. Journal of Infectious Diseases, 1975, 131, 210-216.	1.9	7
83	Effects of Nutritional Recuperation on E-Rosetting Lymphocytes and in Vitro Response to Thymosin in Malnourished Children. Journal of Pediatric Gastroenterology and Nutrition, 1987, 6, 387-391.	0.9	7
84	Shigellosis. , 1982, , 487-509.		7
85	Shiga Toxins. , 2000, 145, 41-63.		6
86	In Vivo Transduction with Shiga Toxin 1-Encoding Phage. Infection and Immunity, 1998, 66, 4496-4498.	1.0	6
87	Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice. Immunology and Cell Biology, 1994, 72, 69-74.	1.0	5
88	The Rediscovery of Shiga Toxin and Its Role in Clinical Disease. Japanese Journal of Medical Science and Biology, 1998, 51, S5-S22.	0.4	5
89	Shigellosis., 2009,, 699-724.		5
90	Malnutrition and Infection., 1979,, 307-332.		4

#	Article	IF	CITATIONS
91	Fecal Excretion of Leukotriene C4 during Human Disease Due to Shigella dysenteriae. Journal of Pediatric Gastroenterology and Nutrition, 1995, 20, 179-183.	0.9	3
92	Perspectives in Foodborne Illness. Infectious Disease Clinics of North America, 2013, 27, 501-515.	1.9	3
93	The Epidemiology and Pathophysiology of Invasive Bacterial Diarrheas. , 1983, , 45-72.		3
94	Extracellular cephalosporinases produced by gram-negative bacilli. Canadian Journal of Microbiology, 1972, 18, 1039-1043.	0.8	2
95	Growth of toxigenic Escherichia coli in Oral Rehydration Solutions. Diagnostic Microbiology and Infectious Disease, 1984, 2, 139-143.	0.8	2
96	Spreading effective AIDS care in poor countries. A commentary on the Partners-in-Health/Zanmi Lasante experience in Haiti Journal of Public Health Policy, 2004, 25, 159-161.	1.0	2
97	Clinical Issues. , 2000, , 181-194.		2
98	Failure of Cholera Enterotoxin to Alter Cyclic $3\hat{a}\in^2$ , $5\hat{a}\in^2$ - Adenosine Monophosphate-Mediated Responses in Toad Urinary Bladder. Infection and Immunity, 1972, 5, 634-635.	1.0	2
99	The multilateral initiative on malaria: past, present, and future. American Journal of Tropical Medicine and Hygiene, 2004, 71, 279-82.	0.6	2
100	The Potential Impact of Nutritional Change on the Global Burden of Viral Disease. Nutrition Reviews, 2009, 58, S55-S62.	2.6	1
101	Molecular Pathogenesis of Giardia lamblia: Adherence and Encystation. , 1991, , 237-247.		1
102	Malnutrition and AIDS in the Developing World. Journal of Nutritional Immunology, 1997, 5, 45-50.	0.1	0
103	Take HEEDif not now, when?. Environmental Health Perspectives, 2004, 112, A144-5.	2.8	0
104	Editorial Commentary: Global Health, Personal Action. Clinical Infectious Diseases, 2004, 38, 879-880.	2.9	0
105	Should global financing be the main priority for pandemic preparedness? – Authors' reply. Lancet, The, 2021, 398, 388-389.	6.3	0
106	An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2 – Authors' reply. Lancet, The, 2021, 398, 1404-1405.	6.3	0